1,517 research outputs found
On the upper limit of antinuclei content in cosmic rays
Upper limit of antinuclei content in cosmic ray
Anatomical practicum in educational process
This paper includes the definition of anatomical practicum, its classification established historically in the educational process, its current reality and the possibilities of an anatomical practicum in future, the ways of its improvement and optimization.Π‘ΡΠ°ΡΡΡ Π²ΠΊΠ»ΡΡΠ°Π΅Ρ Π² ΡΠ΅Π±Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π°Π½Π°ΡΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠ°ΠΊΡΠΈΠΊΡΠΌΠ°, Π΅Π³ΠΎ ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΡ, ΠΈΡΡΠΎΡΠΈΡΠ΅ΡΠΊΠΈ ΡΠ»ΠΎΠΆΠΈΠ²ΡΡΡΡΡ Π² ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎΠΌ ΠΏΡΠΎΡΠ΅ΡΡΠ΅, ΡΠ΅ΠΊΡΡΡΡ ΡΠ΅Π°Π»ΡΠ½ΠΎΡΡΡ ΠΈ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΡΡΠΈ Π°Π½Π°ΡΠΎΠΌΠΈΡΠ΅ΡΠΊΠΎΠ³ΠΎ ΠΏΡΠ°ΠΊΡΠΈΠΊΡΠΌΠ° Π² Π±ΡΠ΄ΡΡΠ΅ΠΌ, ΠΏΡΡΠΈ Π΅Π³ΠΎ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΠΈ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΈ
On the angular distribution of extensive air showers
Angular distributions of extensive air showers with different number of
charged particles in the range 2.5x10^5--4x10^7 are derived using the
experimental data obtained with the EAS MSU array. Possible approximations of
the obtained distributions with different empiric functions available in
literature, are analysed. It is shown that the exponential function provides
the best approximation of the angular distributions in the sense of the
chi-squared criterion.Comment: 5 pages including 1 figur
The Geometry and Moduli of K3 Surfaces
These notes will give an introduction to the theory of K3 surfaces. We begin
with some general results on K3 surfaces, including the construction of their
moduli space and some of its properties. We then move on to focus on the theory
of polarized K3 surfaces, studying their moduli, degenerations and the
compactification problem. This theory is then further enhanced to a discussion
of lattice polarized K3 surfaces, which provide a rich source of explicit
examples, including a large class of lattice polarizations coming from elliptic
fibrations. Finally, we conclude by discussing the ample and Kahler cones of K3
surfaces, and give some of their applications.Comment: 34 pages, 2 figures. (R. Laza, M. Schutt and N. Yui, eds.
ΠΠ΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΡ Π²Π°ΠΊΡΠΈΠ½ ΠΏΡΠΎΡΠΈΠ² COVID-19 Ρ Π±ΠΎΠ»ΡΠ½ΡΡ Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ (ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠ΅ Π΄Π°Π½Π½ΡΠ΅)
Objective: to assess the safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (IRD) in real clinical practice.Patients and methods. A cross-sectional study of patients with IRD, who were admitted to V.A. Nasonova Research Institute of Rheumatology for inpatient or outpatient treatment. All patients received at least 1 dose of vaccine against COVID-19 (main group). The control group consisted of vaccinated persons without IRD. All participants were interviewed by the researcher by filling out a unified questionnaire, additional information was obtained from medical records.Results and discussion. The study included 204 patients with IRD (151 of them were vaccinated with Sputnik V, 31 with Sputnik Light, 19 with Π‘oviVac, 3 with EpiVacCorona; 173 patients received the second component of vaccine) and 131 subjects without IRD (101 of them were vaccinated with Sputnik V, 17 β CoviVak, 5 β Sputnik Light, 2 β EpiVacCorona, 6 β Pfizer/BioNTech; 124 patients received the second component of the vaccine). The number of patients with IRD who had both local and systemic reactions after administration of the first component of the vaccine was significantly less than in the control group (19.6 and 38.9%, respectively; p<0.001). Similar differences were noted after the administration of the second component (15.6 and 27.4%, respectively; p=0.013). Adverse events (AEs) such as pain at the injection site without restriction of movement, weakness, fever, arthralgia/myalgia and chills were significantly more common in the control group after the administration of the first component of the vaccine. After complete immunization, AEs were absent in 35.8% of patients with IRD and in 21% of controls (p=0.006). Exacerbations of IRD and new autoimmune phenomena were not registered in any case.Conclusion. According to preliminary data, vaccination against COVID-19 in patients with IRD appears to be quite safe. Further studies are needed to investigate the safety, immunogenicity, and clinical efficacy of COVID-19 immunization in rheumatic patients.Π¦Π΅Π»Ρ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ β ΠΎΡΠ΅Π½ΠΊΠ° Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ Π²Π°ΠΊΡΠΈΠ½ ΠΏΡΠΎΡΠΈΠ² COVID-19 Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΈΠΌΠΌΡΠ½ΠΎΠ²ΠΎΡΠΏΠ°Π»ΠΈΡΠ΅Π»ΡΠ½ΡΠΌΠΈ ΡΠ΅Π²ΠΌΠ°ΡΠΈΡΠ΅ΡΠΊΠΈΠΌΠΈ Π·Π°Π±ΠΎΠ»Π΅Π²Π°Π½ΠΈΡΠΌΠΈ (ΠΠΠ Π) Π² ΡΠ΅Π°Π»ΡΠ½ΠΎΠΉ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΠΏΡΠ°ΠΊΡΠΈΠΊΠ΅.ΠΠ°ΡΠΈΠ΅Π½ΡΡ ΠΈ ΠΌΠ΅ΡΠΎΠ΄Ρ. ΠΡΠΎΠ²Π΅Π΄Π΅Π½ΠΎ ΠΎΠ΄Π½ΠΎΠΌΠΎΠΌΠ΅Π½ΡΠ½ΠΎΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΏΠΎΡΡΡΠΏΠΈΠ²ΡΠΈΡ
Π½Π° ΡΡΠ°ΡΠΈΠΎΠ½Π°ΡΠ½ΠΎΠ΅ Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΈΠ»ΠΈ ΠΎΠ±ΡΠ°ΡΠΈΠ²ΡΠΈΡ
ΡΡ Π² ΠΊΠΎΠ½ΡΡΠ»ΡΡΠ°ΡΠΈΠ²Π½ΠΎ-Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΡΠ΅ΡΠΊΠΈΠΉ ΡΠ΅Π½ΡΡ Π€ΠΠΠΠ£ Β«ΠΠ°ΡΡΠ½ΠΎ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΡΠΊΠΈΠΉ ΠΈΠ½ΡΡΠΈΡΡΡ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Π.Π. ΠΠ°ΡΠΎΠ½ΠΎΠ²ΠΎΠΉΒ» Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ Π, ΠΏΠΎΠ»ΡΡΠΈΠ²ΡΠΈΡ
ΠΊΠ°ΠΊ ΠΌΠΈΠ½ΠΈΠΌΡΠΌ 1 Π΄ΠΎΠ·Ρ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΏΡΠΎΡΠΈΠ² COVID-19 (ΠΎΡΠ½ΠΎΠ²Π½Π°Ρ Π³ΡΡΠΏΠΏΠ°). ΠΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΡΡ Π³ΡΡΠΏΠΏΡ ΡΠΎΡΡΠ°Π²ΠΈΠ»ΠΈ Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π»ΠΈΡΠ° Π±Π΅Π· ΠΠΠ Π. ΠΡΠ΅ ΡΡΠ°ΡΡΠ½ΠΈΠΊΠΈ Π±ΡΠ»ΠΈ ΠΎΠΏΡΠΎΡΠ΅Π½Ρ Π²ΡΠ°ΡΠΎΠΌ-ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»Π΅ΠΌ Ρ Π·Π°ΠΏΠΎΠ»Π½Π΅Π½ΠΈΠ΅ΠΌ ΡΠ½ΠΈΡΠΈΡΠΈΡΠΎΠ²Π°Π½Π½ΠΎΠΉ Π°Π½ΠΊΠ΅ΡΡ, Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΡ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΡ ΠΏΠΎΠ»ΡΡΠ°Π»ΠΈ ΠΈΠ· ΠΌΠ΅Π΄ΠΈΡΠΈΠ½ΡΠΊΠΎΠΉ Π΄ΠΎΠΊΡΠΌΠ΅Π½ΡΠ°ΡΠΈΠΈ.Π Π΅Π·ΡΠ»ΡΡΠ°ΡΡ ΠΈ ΠΎΠ±ΡΡΠΆΠ΄Π΅Π½ΠΈΠ΅. Π ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ Π²ΠΊΠ»ΡΡΠ΅Π½ΠΎ 204 Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ Π (151 ΠΈΠ· Π½ΠΈΡ
Π±ΡΠ» Π²Π°ΠΊΡΠΈΠ½ΠΈΡΠΎΠ²Π°Π½ Π‘ΠΏΡΡΠ½ΠΈΠΊΠΎΠΌ V, 31 β Π‘ΠΏΡΡΠ½ΠΈΠΊΠΎΠΌ ΠΠ°ΠΉΡ, 19 β ΠΠΎΠ²ΠΈΠΠ°ΠΊΠΎΠΌ, 3 β ΠΠΏΠΈΠΠ°ΠΊΠΠΎΡΠΎΠ½ΠΎΠΉ; Π²ΡΠΎΡΠΎΠΉ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ 173 ΠΏΠ°ΡΠΈΠ΅Π½ΡΠ°) ΠΈ 131 ΠΈΡΠΏΡΡΡΠ΅ΠΌΡΠΉ Π±Π΅Π· ΠΠΠ Π (101 ΠΈΠ· Π½ΠΈΡ
Π±ΡΠ» Π²Π²Π΅Π΄Π΅Π½ Π‘ΠΏΡΡΠ½ΠΈΠΊ V, 17 β ΠΠΎΠ²ΠΈΠΠ°ΠΊ, 5 β Π‘ΠΏΡΡΠ½ΠΈΠΊ ΠΠ°ΠΉΡ, 2 β ΠΠΏΠΈΠΠ°ΠΊΠΠΎΡΠΎΠ½Π°, 6 β Pfizer/BioNTech; Π²ΡΠΎΡΠΎΠΉ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½Ρ Π²Π°ΠΊΡΠΈΠ½Ρ ΠΏΠΎΠ»ΡΡΠΈΠ»ΠΈ 124 ΠΎΠ±ΡΠ»Π΅Π΄ΠΎΠ²Π°Π½Π½ΡΡ
). ΠΠΎΠ»ΠΈΡΠ΅ΡΡΠ²ΠΎ ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ² Ρ ΠΠΠ Π, Ρ ΠΊΠΎΡΠΎΡΡΡ
Π±ΡΠ»ΠΈ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½Ρ ΠΊΠ°ΠΊ ΠΌΠ΅ΡΡΠ½ΡΠ΅, ΡΠ°ΠΊ ΠΈ ΡΠΈΡΡΠ΅ΠΌΠ½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠΈ Π½Π° Π²Π²Π΅Π΄Π΅Π½ΠΈΠ΅ ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ° Π²Π°ΠΊΡΠΈΠ½Ρ, Π±ΡΠ»ΠΎ Π·Π½Π°ΡΠΈΠΌΠΎ ΠΌΠ΅Π½ΡΡΠ΅, ΡΠ΅ΠΌ Π² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ (19,6 ΠΈ 38,9% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ; p<0,001). ΠΠ½Π°Π»ΠΎΠ³ΠΈΡΠ½ΡΠ΅ ΡΠ°Π·Π»ΠΈΡΠΈΡ ΠΎΡΠΌΠ΅ΡΠ°Π»ΠΈΡΡ ΠΈ ΠΏΠΎΡΠ»Π΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ Π²ΡΠΎΡΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ° (15,6 ΠΈ 27,4% ΡΠΎΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΠΎ; p=0,013). Π’Π°ΠΊΠΈΠ΅ Π½Π΅ΠΆΠ΅Π»Π°ΡΠ΅Π»ΡΠ½ΡΠ΅ ΡΠ²Π»Π΅Π½ΠΈΡ (ΠΠ―), ΠΊΠ°ΠΊ Π±ΠΎΠ»Ρ Π² ΠΌΠ΅ΡΡΠ΅ ΠΈΠ½ΡΠ΅ΠΊΡΠΈΠΈ Π±Π΅Π· ΠΎΠ³ΡΠ°Π½ΠΈΡΠ΅Π½ΠΈΡ Π΄Π²ΠΈΠΆΠ΅Π½ΠΈΡ, ΡΠ»Π°Π±ΠΎΡΡΡ, ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΠΌΠΏΠ΅ΡΠ°ΡΡΡΡ ΡΠ΅Π»Π°, Π°ΡΡΡΠ°Π»Π³ΠΈΠΈ/ΠΌΠΈΠ°Π»Π³ΠΈΠΈ ΠΈ ΠΎΠ·Π½ΠΎΠ± Π·Π½Π°ΡΠΈΠΌΠΎ ΡΠ°ΡΠ΅ Π²ΡΡΡΠ΅ΡΠ°Π»ΠΈΡΡ Π² ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΠ΅ ΠΏΠΎΡΠ»Π΅ Π²Π²Π΅Π΄Π΅Π½ΠΈΡ ΠΏΠ΅ΡΠ²ΠΎΠ³ΠΎ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠ° Π²Π°ΠΊΡΠΈΠ½Ρ. ΠΠΎΡΠ»Π΅ ΠΏΠΎΠ»Π½ΠΎΠΉ ΠΈΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΠΈ ΠΠ― ΠΎΡΡΡΡΡΡΠ²ΠΎΠ²Π°Π»ΠΈ Ρ 35,8% Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ Π ΠΈ Ρ 21% Π»ΠΈΡ ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½ΠΎΠΉ Π³ΡΡΠΏΠΏΡ (p=0,006). ΠΠ±ΠΎΡΡΡΠ΅Π½ΠΈΠΉ ΠΠΠ Π ΠΈ Π½ΠΎΠ²ΡΡ
Π°ΡΡΠΎΠΈΠΌΠΌΡΠ½Π½ΡΡ
ΡΠ΅Π½ΠΎΠΌΠ΅Π½ΠΎΠ² Π½Π΅ Π·Π°ΡΠ΅Π³ΠΈΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΎ Π½ΠΈ Π² ΠΎΠ΄Π½ΠΎΠΌ ΡΠ»ΡΡΠ°Π΅.ΠΠ°ΠΊΠ»ΡΡΠ΅Π½ΠΈΠ΅. Π‘ΠΎΠ³Π»Π°ΡΠ½ΠΎ ΠΏΡΠ΅Π΄Π²Π°ΡΠΈΡΠ΅Π»ΡΠ½ΡΠΌ Π΄Π°Π½Π½ΡΠΌ, Π²Π°ΠΊΡΠΈΠ½Π°ΡΠΈΡ ΠΏΡΠΎΡΠΈΠ² COVID-19 Ρ Π±ΠΎΠ»ΡΠ½ΡΡ
Ρ ΠΠΠ Π ΠΏΡΠ΅Π΄ΡΡΠ°Π²Π»ΡΠ΅ΡΡΡ Π΄ΠΎΡΡΠ°ΡΠΎΡΠ½ΠΎ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΠΉ. ΠΠ΅ΠΎΠ±Ρ
ΠΎΠ΄ΠΈΠΌΡ Π΄Π°Π»ΡΠ½Π΅ΠΉΡΠΈΠ΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Ρ ΡΠ΅Π»ΡΡ ΠΈΠ·ΡΡΠ΅Π½ΠΈΡ Π±Π΅Π·ΠΎΠΏΠ°ΡΠ½ΠΎΡΡΠΈ, ΠΈΠΌΠΌΡΠ½ΠΎΠ³Π΅Π½Π½ΠΎΡΡΠΈ ΠΈ ΠΊΠ»ΠΈΠ½ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΠΈΠΌΠΌΡΠ½ΠΈΠ·Π°ΡΠΈΠΈ ΠΏΡΠΎΡΠΈΠ² COVID-19 Ρ ΡΠ΅Π²ΠΌΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ
ΠΏΠ°ΡΠΈΠ΅Π½ΡΠΎΠ²
- β¦